Equities

Tsubota Laboratory Inc

4890:TYO

Tsubota Laboratory Inc

Actions
  • Price (JPY)440.00
  • Today's Change5.00 / 1.15%
  • Shares traded90.40k
  • 1 Year change+5.01%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

  • Revenue in JPY (TTM)1.11bn
  • Net income in JPY-303.08m
  • Incorporated2012
  • Employees7.00
  • Location
    Tsubota Laboratory Inc8FAoyama KK Bldg., 2-26-35, Minami-AoyamaSHINJUKU-KU 160-8582JapanJPN
  • Phone+81 363842866
  • Websitehttps://tsubota-lab.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Veritas In Silico Inc246.24m-148.31m5.87bn15.00--2.55--23.84-23.92-23.9238.93354.610.1227----16,415,930.00-7.39---7.65-------60.23--67.03------101.54--123.38------
Carna Biosciences, Inc.1.40bn-1.51bn5.94bn67.00--2.11--4.24-85.98-85.9880.34147.090.3911.1913.5920,922,580.00-42.15-14.45-45.45-16.9587.5390.59-107.80-35.4211.11--0.0215--17.2416.5914.57---27.69--
Noile-Immune Biotech Inc8.12m-1.07bn7.27bn28.00--1.48--896.12-24.64-24.640.1875113.230.00150.02290.0283289,928.60-19.15---19.61--95.58---13,139.53--79.60-------49.37---192.28------
OncoTherapy Science, Inc.478.75m-1.12bn8.15bn54.00--8.15--17.02-4.86-4.862.043.680.35264.349.778,865,722.00-82.71-55.67-106.53-63.82-32.12-1.49-234.61-247.473.11--0.0731---46.2416.81-15.15---48.33--
TMS Co Ltd0.00-1.10bn8.27bn14.00--2.77-----28.37-28.370.0074.100.00----0.00-33.57---34.42----------31.13--0.00-------11.51------
Linical Co Ltd11.67bn-121.16m8.54bn662.00--1.0620.770.7314-5.36-5.36516.67326.900.6575--3.7417,628,030.00-0.68264.01-1.186.3326.6330.99-1.045.48--2.650.258850.81-1.671.70-66.32-9.86-10.184.56
Modalis Therapeutics Corp0.00-1.87bn9.23bn37.00--3.00-----52.79-52.790.0044.350.00----0.00-74.95-29.19-78.46-30.02-------597.3543.87-87.460.0771---100.00--11.50--135.50--
Chiome Bioscience Inc581.07m-1.22bn9.37bn51.00--7.56--16.12-22.07-22.0710.5319.850.33715.168.0111,393,550.00-70.61-50.50-95.97-57.3853.5557.53-209.45-224.743.57-894.370.1995--8.1926.241.84------
Medinet Co Ltd768.50m-1.28bn10.58bn98.00--2.04--13.77-5.04-5.043.0519.620.135611.153.46---22.53-21.15-23.83-22.3914.6622.97-166.17-160.1918.45--0.0002--16.17-6.2111.19---11.16--
3-D Matrix Ltd5.25bn-1.05bn11.06bn106.00--9.52--2.11-12.89-12.8966.8811.660.85590.5515.4049,502,420.00-17.15-42.10-21.31-55.6068.3853.95-20.04-96.032.51--0.7979--98.3069.4189.55---30.34--
Tsubota Laboratory Inc1.11bn-303.08m11.13bn7.00--7.88--10.02-12.09-12.0943.1555.210.48991.605.16158,704,300.00-13.37---18.33--52.59---27.28--2.57-24.640.0678---29.45---811.14------
PRISM BioLab Co Ltd-100.00bn-100.00bn11.83bn22.00--5.60----------58.79----------------------------0.00---79.63---822.18------
Nano Mrna Co Ltd52.10m-821.00m11.87bn18.00--3.88--227.74-11.66-11.660.7443.300.01027.011.562,894,445.00-16.13-24.16-17.89-25.1780.7284.69-1,575.81-600.708.17--0.2662---32.98-22.8840.50------
AnGes Inc521.96m-9.80bn14.46bn145.00--0.6128--27.71-45.15-45.152.4286.480.01740.232411.183,599,697.00-32.66-28.50-36.48-33.1437.0839.42-1,876.83-6,726.822.36-12.150.0672--128.13-24.1749.45--12.11--
Chordia Therapeutics Inc0.00-1.83bn15.14bn21.00--3.63-----31.95-31.950.0061.49---------------------------500.25---------918.09------
Data as of Nov 22 2024. Currency figures normalised to Tsubota Laboratory Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

1.27%Per cent of shares held by top holders
HolderShares% Held
Asset Management One Co., Ltd.as of 31 Oct 2023284.60k1.11%
Simplex Asset Management Co., Ltd.as of 07 Nov 202438.20k0.15%
Mitsubishi UFJ Asset Management Co., Ltd.as of 27 Feb 2023800.000.00%
Fivestar Asset Management Co. Ltd.as of 25 Oct 20230.000.00%
More ▼
Data from 25 Apr 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.